Connect your AI

Bio-Techne TECH Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

RevvityRVTY

$5.44M+107%

Bio-Rad LaboratoriesBIO

$3.4M-20.9%

Agilent TechnologiesA

$1M0.0%

Charles River LaboratoriesCRL

$1.22M—

WAT

Waters CorporationWAT

$3M-62.5%

AbbottABT

$116M-59.6%

Other financials

Income statement

Revenue$311.4M-1.5%

Gross profit$208.3M-2.9%

Operating income$75.5M+95.0%

Net income$51.0M+126%

EPS (diluted)$0.32+129%

Balance sheet

Cash & equivalents$209.8M+49.2%

Total debt$290.3M-31.4%

Total equity$2.1B+3.3%

Total assets$2.6B-3.5%

Cash flow

Operating cash flow$86.7M+111%

CapEx$9.1M-10.2%

Free cash flow$77.6M+150%

Valuation

Market cap$9.07B-11.8%

Enterprise value$9.15B-13.6%

P/E60.6×+13.6×

P/S7.5×-1.0×

Profitability

Gross margin65%-0.8pp

Operating margin14.2%-7.9pp

Net margin10.9%-6.7pp

FCF margin22.3%+4.0pp

Returns & leverage

Return on equity6.5%-3.9pp

Debt / equity0.1×-0.1×

Current ratio4.5×+0.8×

Where this comes from

Reported directly by Bio-Techne in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: Bio-Techne’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bio-Techne's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Bio-Techne's stock issuance proceeds?: Bio-Techne (TECH) reported stock issuance proceeds of $29.96M in Q1 2026.
How has Bio-Techne's stock issuance proceeds changed year-over-year?: Bio-Techne's stock issuance proceeds increased by 101.4% year-over-year, from $14.87M to $29.96M.
What is the long-term trend for Bio-Techne's stock issuance proceeds?: Over 4 years (2021 to 2025), Bio-Techne's stock issuance proceeds has grown at a -5.6% compound annual growth rate (CAGR), from $65.09M to $51.74M.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.